Needham initiated coverage of GH Research (GHRS) with a Buy rating and $19 price target The company’s GH001 demonstrated “impressive efficacy” in Phase 2 and “potentially game-changing” 73% remission rate at six months with re-treatments, the analyst tells investors in a research note. Needham estimates GH001 could be a significant opportunity with sales of $1.9B in U.S. by 2035.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- GH Research Presents Promising GH001 Trial Data at ECNP 2025
- Psychedelic: PharmAla launches portal for MDMA prescribers, therapists
- GH Research Showcases Promising Depression Treatment at ECNP 2025
- GH Research to Join TD Cowen Neuropsychiatry Summit
- GH Research Presents Promising Trial Results for GH001 at ISBD 2025